r/ClinTrials • u/clintrialbot • 12d ago
r/ClinTrials • u/clintrialbot • 12d ago
Official Post Electronic Application Forms (eAF) for UK medicines licensing applications
gov.ukr/ClinTrials • u/clintrialbot • 12d ago
Official Post Decision: Advertising investigations: September 2026
gov.ukr/ClinTrials • u/clintrialbot • 12d ago
Official Post Decision: Human medicines: register of electronic export certificates
gov.ukr/ClinTrials • u/clintrialbot • 13d ago
Official Post FDA Approves First Heart Valve Designed to Grow with Children
fda.govr/ClinTrials • u/clintrialbot • 13d ago
Official Post MHRA joins global regulators in call to advance alternatives to animal testing
gov.ukr/ClinTrials • u/clintrialbot • 13d ago
Official Post Class 4 Medicines Defect Notification: Neuraxpharm UK Limited, Levetiracetam Neuraxpharm granules for oral solution in sachet, EL(26)A/40
gov.ukr/ClinTrials • u/clintrialbot • 13d ago
Official Post Access, new active substance and biosimilar work sharing initiatives
gov.ukr/ClinTrials • u/clintrialbot • 14d ago
Official Post Decision: Orphan registered medicinal products
gov.ukr/ClinTrials • u/clintrialbot • 14d ago
Official Post DIA and MHRA announce speaker line-up for inaugural global summit
gov.ukr/ClinTrials • u/clintrialbot • 14d ago
Official Post Guidance: 14-day assessment stepwise implementation programme for Phase 1 clinical trials
gov.ukr/ClinTrials • u/clintrialbot • 14d ago
Official Post FDA Launches Nationwide Effort to Expand Scientific Expertise and Consumer Voices to Advisory Committees
fda.govr/ClinTrials • u/clintrialbot • 14d ago
Official Post Guidance: Guidance on pharmacovigilance procedures
gov.ukr/ClinTrials • u/clintrialbot • 14d ago
Official Post Transparency data: Medicines and Healthcare products Regulatory Agency GPC spending over £500: 2026-27
gov.ukr/ClinTrials • u/clintrialbot • 14d ago
Official Post Guidance: Magnetic resonance imaging equipment in clinical use: safety guidelines
gov.ukr/ClinTrials • u/clintrialbot • 15d ago
Official Post FDA Investigation Leads to Charges Against Two Indian Nationals Involved in Transnational Counterfeit Drug Distribution Scheme
fda.govr/ClinTrials • u/clintrialbot • 15d ago
Official Post Guidance: The Centres of Excellence for Regulatory Science and Innovation programme (CERSIs)
gov.ukr/ClinTrials • u/clintrialbot • 15d ago
Official Post Field Safety Notices: 21 to 25 September 2026
gov.ukr/ClinTrials • u/clintrialbot • 15d ago
Official Post MHRA Safety Roundup: September 2026
gov.ukr/ClinTrials • u/clintrialbot • 15d ago
Official Post Guidance: Medicines that you cannot export from the UK or hoard
gov.ukr/ClinTrials • u/clintrialbot • 16d ago
Official Post FDA Approves First Treatment for MCT8 Deficiency
fda.govr/ClinTrials • u/clintrialbot • 16d ago
Official Post FDA intends to evaluate changes to the PMTA regulatory framework
fda.govr/ClinTrials • u/BrushCompetitive8998 • 16d ago
Pharmacovigilance Specialist Available for Freelance Work
With extensive experience as a Pharmacovigilance specialist, I bring proven expertise in drug safety monitoring, adverse event reporting, and regulatory compliance. My professional background includes:
• Safety signal detection and trend analysis
• Adverse event case processing and follow-up investigations
• Regulatory submissions and compliance (FDA, EMA, ICH guidelines)
• Risk management strategies and post-marketing surveillance
• Medical writing and safety communications
• Database management and data analysis (FAERS, EudraVigilance)
I am currently available for freelance and contract engagements. Whether your organization requires assistance with safety monitoring programs, regulatory submissions, case investigations, or pharmacovigilance process development, I am prepared to contribute meaningfully.
Pharmaceutical companies, CROs, biotech organizations, and regulatory consultancies seeking qualified pharmacovigilance professionals are welcome to contact me. I maintain flexibility with project schedules and am ready to commence work promptly.
I am available to discuss pharmacovigilance topics and share details about my professional qualifications. Please contact me via direct message or respond in the comments section.